Diabetic Retinopathy Market: By Drug Type, By Route of Administration, By Distribution Channel, and Region Forecast 2020-2031
Diabetic retinopathy market size was valued at US$ 9.5 billion in 2024 and is expected to reach US$ 14.7 billion by 2031, growing at a significant CAGR of 6.4% from 2025-2031. Diabetic retinopathy is the most common form of diabetic eye disease. Diabetic retinopathy usually affects people with diabetes for a number of years. High glucose levels in the cause damage to the retinal blood vessels is the main manifestation of diabetic retinopathy. In some other cases, the retinal blood vessels will be swollen (macular oedema) with a fluid leaking into rear of eye. In few cases, on the surface of the retinal blood vessels will grow abnormally. If market is not properly treated, can progressively become more serious and seriously affect vision which may lead to blindness. Diabetic retinopathy can be treated by various methods depending on the stage of the disease. Diabetic retinopathy is one of the major causes of blindness in the adult population in America.
As per, the World Health Organisation (WHO), 347 Mn people were suffering from diabetes globally in 2012, in which 11% population had diabetic retinopathy. An increase in focus on Asia-Pacific and LAMEA regions by various vendors is expected to boost the market growth of the market According to the World Bank, in 2015,10.4% of rate of prevalence of diabetes was observed in Brazil. Strategic acquisitions, geographic expansion, agreements, partnerships, and new product launches are the most vital strategic implementations by most of the companies in the market of diabetic retinopathy.
Study Period
2025-2031Base Year
2024CAGR
6.4%Largest Market
North-AmericaFastest Growing Market
Europe
Diabetic Retinopathy will affect both type 1 and type 2 diabetic patients and due to the abundant increase in the pool of patients with Diabetes, According to the World Health Organisation (WHO), 41 % of global population with diabetes are geriatric patients which is highly attributing the growth of the diabetic retinopathy market. Furthermore, rise in healthcare infrastructure up-gradation, rise in demand for the early diagnosis devices are the few factors having significant impact in driving the market. However, paucity of skilled ophthalmologist, lack of primary infrastructure and insurance facilities are some of the restraining factors that are hampering the growth of the market.
North America dominates the market followed by Asia-Pacific and Europe. The factors that are attributing for the market growth in North America are, people with high obesity rates are more prone to diabetes conditions. Large patient pool in European region with diabetic retinopathy is expected to drive the growth of the market. In emerging economies, due to the improvement in the healthcare infrastructure and rise in awareness in the people Owing to improved infrastructure and awareness among the people, improving on the quality of life (QALY) in diabetic patients, rise in demand of early detection and treatment of chronic conditions such as diabetic retinopathy are the factors that are driving the growth of the diabetic retinopathy market in Asia Pacific regions.
Latin America
Europe
Asia Pacific
Middle East
North America
|
Report Benchmarks |
Details |
|
Report Study Period |
2025-2031 |
|
Market Size in 2024 |
US$ 9.5 billion |
|
Market Size in 2031 |
US$ 14.7 billion |
|
Market CAGR |
6.4% |
|
By Type |
|
|
By Drug Class |
|
|
By Distribution Channel |
|
|
By Region |
|
Download Free Sample Report
Diabetic retinopathy market size was valued at US$ 9.5 billion in 2024 and is expected to reach US$ 14.7 billion by 2031, growing at a significant CAGR of 6.4%.
Abbott Laboratories (U.S.), Alimera Sciences (U.S.), Allergan plc (Ireland.), Ampio Pharmaceuticals. (U.S.), Bayer AG (Germany), F. Hoffmann-La Roche (Switzerland), Novartis AG (Switzerland), Pfizer Inc. (U.S.), Regeneron Pharmaceuticals Inc. (U.S.), Valeant (Canada)
Europe is the fastest-growing region in the diabetic retinopathy market
| 1. Executive Summary |
| 2. Global Diabetic Retinopathy Market Introduction |
| 2.1. Global Diabetic Retinopathy Market - Taxonomy |
| 2.2. Global Diabetic Retinopathy Market - Definitions |
| 2.2.1. Drug Type |
| 2.2.2. Route of Administration |
| 2.2.3. Distribution Channel |
| 3. Global Diabetic Retinopathy Market Dynamics |
| 3.1. Drivers |
| 3.2. Restraints |
| 3.3. Opportunities/Unmet Needs of the Market |
| 3.4. Trends |
| 3.5. Global Diabetic Retinopathy Treatment Market Dynamic Factors - Impact Analysis |
| 3.6. Global Diabetic Retinopathy Treatment Market Competition Landscape |
| 4. Global Diabetic Retinopathy Market, By Drug Type, 2020-2024 and Forecast 2025-2031 (Revenue, USD Mn) |
| 4.1. Aflibercept |
| 4.1.1. Market Analysis, 2020-2024 and Forecast 2025-2031 (Revenue, USD Mn) |
| 4.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 4.1.3. Market Opportunity Analysis |
| 4.2. Ranibizumab |
| 4.2.1. Market Analysis, 2020-2024 and Forecast 2025-2031 (Revenue, USD Mn) |
| 4.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 4.2.3. Market Opportunity Analysis |
| 4.3. Corticosteroids |
| 4.3.1. Market Analysis, 2020-2024 and Forecast 2025-2031 (Revenue, USD Mn) |
| 4.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 4.3.3. Market Opportunity Analysis |
| 4.4. Others |
| 4.4.1. Market Analysis, 2020-2024 and Forecast 2025-2031 (Revenue, USD Mn) |
| 4.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 4.4.3. Market Opportunity Analysis |
| 5. Global Diabetic Retinopathy Treatment Market Forecast, By Route of Administration, 2019 - 2023 and Forecast, 2021 2027 (Revenue, USD Mn) |
| 5.1. Oral |
| 5.1.1. Market Analysis, 2020-2024 and Forecast 2025-2031 (Revenue, USD Mn) |
| 5.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 5.1.3. Market Opportunity Analysis |
| 5.2. Parenteral |
| 5.2.1. Market Analysis, 2020-2024 and Forecast 2025-2031 (Revenue, USD Mn) |
| 5.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 5.2.3. Market Opportunity Analysis |
| 5.3. Others |
| 5.3.1. Market Analysis, 2020-2024 and Forecast 2025-2031 (Revenue, USD Mn) |
| 5.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 5.3.3. Market Opportunity Analysis |
| 6. Global Diabetic Retinopathy Treatment Market, By Distribution Channel, 2020-2024 and Forecast 2025-2031 (Revenue, USD Mn) |
| 6.1. HOSPITAL PHARMACIES |
| 6.1.1. Market Analysis, 2020-2024 and Forecast 2025-2031 (Revenue, USD Mn) |
| 6.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 6.1.3. Market Opportunity Analysis |
| 6.2. RETAIL PHARMACIES |
| 6.2.1. Market Analysis, 2020-2024 and Forecast 2025-2031 (Revenue, USD Mn) |
| 6.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 6.2.3. Market Opportunity Analysis |
| 6.3. ONLINE PHARMACIES |
| 6.3.1. Market Analysis, 2020-2024 and Forecast 2025-2031 (Revenue, USD Mn) |
| 6.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 6.3.3. Market Opportunity Analysis |
| 7. Global Diabetic Retinopathy Treatment Market Forecast, By Region, 2020-2024 and Forecast 2025-2031 (Revenue, USD Mn) |
| 7.1. North America |
| 7.1.1. Market Analysis, 2020-2024 and Forecast 2025-2031 (Revenue, USD Mn) |
| 7.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 7.1.3. Market Opportunity Analysis |
| 7.2. Europe |
| 7.2.1. Market Analysis, 2020-2024 and Forecast 2025-2031 (Revenue, USD Mn) |
| 7.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 7.2.3. Market Opportunity Analysis |
| 7.3. Asia-Pacific |
| 7.3.1. Market Analysis, 2020-2024 and Forecast 2025-2031 (Revenue, USD Mn) |
| 7.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 7.3.3. Market Opportunity Analysis |
| 7.4. Latin America |
| 7.4.1. Market Analysis, 2020-2024 and Forecast 2025-2031 (Revenue, USD Mn) |
| 7.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 7.4.3. Market Opportunity Analysis |
| 7.5. Middle East and Africa |
| 7.5.1. Market Analysis, 2020-2024 and Forecast 2025-2031 (Revenue, USD Mn) |
| 7.5.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 7.5.3. Market Opportunity Analysis |
| 7.6. Global Diabetic Retinopathy Treatment Market - Opportunity Analysis Index, By Drug Type, Route of Administration, Distribution Channel and Region, 2024-2030 |
| 8. North America Diabetic Retinopathy Treatment MarketAnalysis,2020-2024 and Forecast 2025-2031 (Revenue, USD Mn) |
| 8.1. By Drug Type Analysis 2019 - 2023 and Forecast 2024-2030by Revenue (USD Mn),Y-o-Y Growth (%), and Market Share (%) |
| 8.1.1. Aflibercept |
| 8.1.2. Ranibizumab |
| 8.1.3. Corticosteroids |
| 8.1.4. Others |
| 8.2. Route of Administration Analysis 2019 - 2023 and Forecast 2024-2030 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%) |
| 8.2.1. Oral |
| 8.2.2. Parenteral |
| 8.2.3. Others |
| 8.3. Distribution Channel Analysis 2019 - 2023 and Forecast 2024-2030 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%) |
| 8.3.1. HOSPITAL PHARMACIES |
| 8.3.2. RETAIL PHARMACIES |
| 8.3.3. ONLINE PHARMACIES |
| 8.4. Country Analysis 2019 - 2023 and Forecast 2024-2030by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%) |
| 8.4.1. USA |
| 8.4.2. Canada |
| 8.5. North America Diabetic Retinopathy Treatment Market - Opportunity Analysis Index, By Drug Type, Route of Administration, Distribution Channel, and Country, 2024-2030 |
| 8.6. North America Diabetic Retinopathy Treatment Market Dynamics Trends |
| 9. Europe Diabetic Retinopathy Treatment Market Analysis, 2020-2024 and Forecast 2025-2031 (Revenue, USD Mn) |
| 9.1. By Drug Type Analysis 2019 - 2023 and Forecast 2024-2030by Revenue (USD Mn),Y-o-Y Growth (%), and Market Share (%) |
| 9.1.1. Aflibercept |
| 9.1.2. Ranibizumab |
| 9.1.3. Corticosteroids |
| 9.1.4. Others |
| 9.2. Route of Administration Analysis 2019 - 2023 and Forecast 2024-2030 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%) |
| 9.2.1. Oral |
| 9.2.2. Parenteral |
| 9.2.3. Others |
| 9.3. Distribution Channel Analysis 2019 - 2023 and Forecast 2024-2030 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%) |
| 9.3.1. HOSPITAL PHARMACIES |
| 9.3.2. RETAIL PHARMACIES |
| 9.3.3. ONLINE PHARMACIES |
| 9.4. Country Analysis 2019 - 2023 and Forecast 2024-2030 by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%) |
| 9.4.1. Germany |
| 9.4.2. UK |
| 9.4.3. France |
| 9.4.4. Spain |
| 9.4.5. Italy |
| 9.4.6. Russia |
| 9.4.7. Poland |
| 9.4.8. Rest of Europe |
| 9.5. Europe Diabetic Retinopathy Treatment Market - Opportunity Analysis Index, By Drug Type, Route of Administration, Distribution Channel, and Country, 2024-2030 |
| 9.6. Europe Diabetic Retinopathy Treatment Market Dynamics Trends |
| 10. Asia-Pacific Diabetic Retinopathy Treatment Market Analysis, 2020-2024 and Forecast 2025-2031 (Revenue, USD Mn) |
| 10.1. By Drug Type Analysis 2019 - 2023 and Forecast 2024-2030by Revenue (USD Mn),Y-o-Y Growth (%), and Market Share (%) |
| 10.1.1. Aflibercept |
| 10.1.2. Ranibizumab |
| 10.1.3. Corticosteroids |
| 10.1.4. Others |
| 10.2. Route of Administration Analysis 2019 - 2023 and Forecast 2024-2030 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%) |
| 10.2.1. Oral |
| 10.2.2. Parenteral |
| 10.2.3. Others |
| 10.3. Distribution Channel Analysis 2019 - 2023 and Forecast 2024-2030 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%) |
| 10.3.1. HOSPITAL PHARMACIES |
| 10.3.2. RETAIL PHARMACIES |
| 10.3.3. ONLINE PHARMACIES |
| 10.4. Country Analysis2019 - 2023 and Forecast 2024-2030 by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%) |
| 10.4.1. Japan |
| 10.4.2. China |
| 10.4.3. India |
| 10.4.4. ASEAN |
| 10.4.5. Australia & New Zealand |
| 10.4.6. Rest of Asia-Pacific |
| 10.5. Asia-Pacific Diabetic Retinopathy Treatment Market - Opportunity Analysis Index, By Drug Type, Route of Administration, Distribution Channel, and Country, 2024-2030 |
| 10.6. Asia-Pacific Diabetic Retinopathy Treatment Market Dynamics Trends |
| 11. Latin America Diabetic Retinopathy Treatment Market Analysis, 2020-2024 and Forecast 2025-2031 (Revenue, USD Mn) |
| 11.1. By Drug Type Analysis 2019 - 2023 and Forecast 2024-2030by Revenue (USD Mn),Y-o-Y Growth (%), and Market Share (%) |
| 11.1.1. Aflibercept |
| 11.1.2. Ranibizumab |
| 11.1.3. Corticosteroids |
| 11.1.4. Others |
| 11.2. Route of Administration Analysis 2019 - 2023 and Forecast 2024-2030 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%) |
| 11.2.1. Oral |
| 11.2.2. Parenteral |
| 11.2.3. Others |
| 11.3. Distribution Channel Analysis 2019 - 2023 and Forecast 2024-2030 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%) |
| 11.3.1. HOSPITAL PHARMACIES |
| 11.3.2. RETAIL PHARMACIES |
| 11.3.3. ONLINE PHARMACIES |
| 11.4. Country Analysis 2019 - 2023 and Forecast 2024-2030 by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%) |
| 11.4.1. Brazil |
| 11.4.2. Mexico |
| 11.4.3. Argentina |
| 11.4.4. Rest of Latin America |
| 11.5. Latin America Diabetic Retinopathy Treatment Market - Opportunity Analysis Index, By Drug Type, Route of Administration, Distribution Channel, and Country, 2024-2030 |
| 11.6. Latin America Diabetic Retinopathy Treatment Market Dynamics Trends |
| 12. Middle East and Africa Diabetic Retinopathy Treatment Market Analysis, 2020-2024 and Forecast 2025-2031 (Revenue, USD Mn) |
| 12.1. By Drug Type Analysis 2019 - 2023 and Forecast 2024-2030by Revenue (USD Mn),Y-o-Y Growth (%), and Market Share (%) |
| 12.1.1. Aflibercept |
| 12.1.2. Ranibizumab |
| 12.1.3. Corticosteroids |
| 12.1.4. Others |
| 12.2. Route of Administration Analysis 2019 - 2023 and Forecast 2024-2030 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%) |
| 12.2.1. Oral |
| 12.2.2. Parenteral |
| 12.2.3. Others |
| 12.3. Distribution Channel Analysis 2019 - 2023 and Forecast 2024-2030 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%) |
| 12.3.1. HOSPITAL PHARMACIES |
| 12.3.2. RETAIL PHARMACIES |
| 12.3.3. ONLINE PHARMACIES |
| 12.4. Country Analysis 2019 - 2023 and Forecast 2024-2030 by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%) |
| 12.4.1. Gulf Cooperation Council (GCC) Countries |
| 12.4.2. Israel |
| 12.4.3. South Africa |
| 12.4.4. Rest of MEA |
| 12.5. MEA Diabetic Retinopathy Treatment Market - Opportunity Analysis Index, By Drug Type, Route of Administration, Distribution Channel, and Country, 2024-2030 |
| 12.6. MEA Diabetic Retinopathy Treatment Market Dynamics Trends |
| 13. Global Diabetic Retinopathy Treatment - Pipeline Drug Analysis |
| 13.1. Global Diabetic Retinopathy Treatment Disease Epidemiology |
| 13.2 Global Diabetic Retinopathy Treatment, Pipeline Drugs Assessment |
| 13.3. Global Diabetic Retinopathy Treatment, Pipeline Drugs Assessment - Sponsors/Companies |
| 14. Competition Landscape |
| 14.1. Strategic Dashboard of Top Market Players |
| 14.2. Company Profiles (Introduction, Financial Analysis, Route of Administration& Service Offerings, Key Developments, Strategies, and SWOT Analysis) |
| 14.2.1. Regeneron Pharmaceuticals |
| 14.2.2. Novartis AG |
| 14.2.3. Genentech |
| 14.2.4. Novartis AG |
| 14.2.5. Bayer AG |
| 14.2.6. Oxurion |
| 14.2.7. OccuRx |
| 14.2.8. AptaBio Therapeutics |
| 14.2.9. Kodiak Sciences |
| 14.2.10. RemeGen |
| 14.2.11. F. Hoffman-La-Roche AG. |
| 14.2.12. Grifols S.A. |
| 15. Research Methodology |
| 16. Key Assumptions and Acronymsc |
Key Market Players
Author
Muni Kumar Meravath is a seasoned Healthcare Market Research Analyst with over 6 years of experience in the healthcare domain, encompassing pharmaceuticals, medical devices, and diagnostics. A graduate in Pharmacy, he possesses a strong foundation in the intricacies of the healthcare sector. He further enhanced his expertise by pursuing an MBA in Pharmaceuticals, equipping him with valuable business acumen. His analytical skills and market insights have contributed to strategic decision-making and enhanced market positioning for various healthcare organizations. Committed to driving innovation and excellence, Muni continues to seek opportunities to improve healthcare delivery through data-driven insights.
Download Sample
